These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22065318)

  • 1. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
    Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB
    J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
    Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
    Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma.
    Mizuno S; Isaji S; Tanemura A; Kishiwada M; Murata Y; Azumi Y; Kuriyama N; Usui M; Sakurai H; Tabata M
    J Gastrointest Surg; 2014 Jun; 18(6):1209-15. PubMed ID: 24664421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H
    Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
    Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
    Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
    J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
    J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
    Vicente E; Quijano Y; Ielpo B; Duran H
    Surg Oncol; 2017 Sep; 26(3):276-277. PubMed ID: 29804945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant strategies for pancreatic cancer.
    Evans DB; Wolff RA; Crane CH
    Oncology (Williston Park); 2001 Jun; 15(6):727-37; discussion 741-4, 747. PubMed ID: 11430206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
    Hong TS; Ryan DP; Borger DR; Blaszkowsky LS; Yeap BY; Ancukiewicz M; Deshpande V; Shinagare S; Wo JY; Boucher Y; Wadlow RC; Kwak EL; Allen JN; Clark JW; Zhu AX; Ferrone CR; Mamon HJ; Adams J; Winrich B; Grillo T; Jain RK; DeLaney TF; Fernandez-del Castillo C; Duda DG
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):830-8. PubMed ID: 24867540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
    Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Liu DN; Lv A; Tian ZH; Tian XY; Guan XY; Dong B; Zhao M; Hao CY
    Oncotarget; 2017 Jan; 8(5):7766-7776. PubMed ID: 27999192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
    Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
    J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma.
    Butler JR; Ahmad SA; Katz MH; Cioffi JL; Zyromski NJ
    HPB (Oxford); 2016 Apr; 18(4):305-11. PubMed ID: 27037198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.